Pharmacodynamic Characterization of the Efficacy Signals Due to Selective BRAF Inhibition with PLX4032 in Malignant Melanoma

Curtin, 2005, Distinct sets of genetic alterations in melanoma, N Engl J Med, 353, 2135, 10.1056/NEJMoa050092 Curtin, 2006, Somatic activation of KIT in distinct subtypes of melanoma, J Clin Oncol, 24, 4340, 10.1200/JCO.2006.06.2984 Landi, 2006, MC1R germline variants confer risk for BRAF-mutant melanoma, Science, 313, 521, 10.1126/science.1127515 Kim, 2008, Phase II trial of imatinib mesylate in patients with metastatic melanoma, Br J Cancer, 99, 734, 10.1038/sj.bjc.6604482 Amaravadi, 2009, Phase II trial of temozolomide and sorafenib in advanced melanoma patients with or without brain metastases, Clin Cancer Res, 15, 7711, 10.1158/1078-0432.CCR-09-2074 Cohen, 2002, Mitogen-activated protein kinase activation is an early event in melanoma progression, Clin Cancer Res, 8, 3728 Gray-Schopfer, 2007, Melanoma biology and new targeted therapy, Nature, 445, 851, 10.1038/nature05661 Pratilas, 2009, (V600E)BRAF is associated with disabled feedback inhibition of RAF-MEK signaling and elevated transcriptional output of the pathway, Proc Natl Acad Sci USA, 106, 4519, 10.1073/pnas.0900780106 Kantrow, 2007, Expression of activated Akt in benign nevi, Spitz nevi and melanomas, J Cutan Pathol, 34, 593, 10.1111/j.1600-0560.2006.00675.x Cheung, 2008, Akt3 and mutant V600E B-Raf cooperate to promote early melanoma development, Cancer Res, 68, 3429, 10.1158/0008-5472.CAN-07-5867 Dankort, 2009, Braf(V600E) cooperates with Pten loss to induce metastatic melanoma, Nat Genet, 41, 544, 10.1038/ng.356 Gray-Schopfer, 2007, Tumor necrosis factor-alpha blocks apoptosis in melanoma cells when BRAF signaling is inhibited, Cancer Res, 67, 122, 10.1158/0008-5472.CAN-06-1880 Sala, 2008, BRAF silencing by short hairpin RNA or chemical blockade by PLX4032 leads to different responses in melanoma and thyroid carcinoma cells, Mol Cancer Res, 6, 751, 10.1158/1541-7786.MCR-07-2001 Chapman, 2009, Early efficacy signal demonstrated in advanced melanoma in a phase I trial of the oncogenic BRAF-selective inhibitor PLX4032, Eur J Cancer, 7, 5, 10.1016/S1359-6349(09)72036-1 Sondak, 2009, Targeting mutant BRAF and KIT in metastatic melanoma: ASCO 2009 meeting report, Pigment Cell Melanoma Res, 22, 386, 10.1111/j.1755-148X.2009.00593.x Finn, 2009, PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro, Breast Cancer Res, 11, R77, 10.1186/bcr2419 Yamoutpour, 2008, Gene silencing for epidermal growth factor receptor variant III induces cell-specific cytotoxicity, Mol Cancer Ther, 7, 3586, 10.1158/1535-7163.MCT-08-0653 Fargnoli, 2008, MC1R variants increase risk of melanomas harboring BRAF mutations, J Invest Dermatol, 128, 2485, 10.1038/jid.2008.67 Tsao, 2004, Genetic interaction between NRAS and BRAF mutations and PTEN/MMAC1 inactivation in melanoma, J Invest Dermatol, 122, 337, 10.1046/j.0022-202X.2004.22243.x Solit, 2006, BRAF mutation predicts sensitivity to MEK inhibition, Nature, 439, 358, 10.1038/nature04304 Abi-Habib, 2005, BRAF status and mitogen-activated protein/extracellular signal-regulated kinase kinase 1/2 activity indicate sensitivity of melanoma cells to anthrax lethal toxin, Mol Cancer Ther, 4, 1303, 10.1158/1535-7163.MCT-05-0145 Christensen, 2005, Growth factors rescue cutaneous melanoma cells from apoptosis induced by knockdown of mutated (V 600 E) B-RAF, Oncogene, 24, 6292, 10.1038/sj.onc.1208758 Hao, 2007, Context-dependent roles of mutant B-Raf signaling in melanoma and colorectal carcinoma cell growth, Mol Cancer Ther, 6, 2220, 10.1158/1535-7163.MCT-06-0728 Soh, 2009, Oncogene mutations, copy number gains and mutant allele specific imbalance (MASI) frequently occur together in tumor cells, PLoS One, 4, e7464, 10.1371/journal.pone.0007464 Bittner, 2000, Molecular classification of cutaneous malignant melanoma by gene expression profiling, Nature, 406, 536, 10.1038/35020115 Shields, 2007, Lack of extracellular signal-regulated kinase mitogen-activated protein kinase signaling shows a new type of melanoma, Cancer Res, 67, 1502, 10.1158/0008-5472.CAN-06-3311 Hoek, 2006, Metastatic potential of melanomas defined by specific gene expression profiles with no BRAF signature, Pigment Cell Res, 19, 290, 10.1111/j.1600-0749.2006.00322.x Schepsky, 2006, The microphthalmia-associated transcription factor Mitf interacts with β-catenin to determine target gene expression, Mol Cell Biol, 26, 8914, 10.1128/MCB.02299-05 Du, 2004, Critical role of CDK2 for melanoma growth linked to its melanocyte-specific transcriptional regulation by MITF, Cancer Cell, 6, 565, 10.1016/j.ccr.2004.10.014 Topol, 2003, Wnt-5a inhibits the canonical Wnt pathway by promoting GSK-3-independent β-catenin degradation, J Cell Biol, 162, 899, 10.1083/jcb.200303158 Fedi, 1999, Isolation and biochemical characterization of the human Dkk-1 homologue, a novel inhibitor of mammalian Wnt signaling, J Biol Chem, 274, 19465, 10.1074/jbc.274.27.19465 Finch, 1997, Purification and molecular cloning of a secreted, Frizzled-related antagonist of Wnt action, Proc Natl Acad Sci USA, 94, 6770, 10.1073/pnas.94.13.6770 Weeraratna, 2002, Wnt5a signaling directly affects cell motility and invasion of metastatic melanoma, Cancer Cell, 1, 279, 10.1016/S1535-6108(02)00045-4 O’Connell, 2010, The orphan tyrosine kinase receptor, ROR2, mediates Wnt5A signaling in metastatic melanoma, Oncogene, 29, 34, 10.1038/onc.2009.305 Dissanayake, 2008, Wnt5A regulates expression of tumor-associated antigens in melanoma via changes in signal transducers and activators of transcription 3 phosphorylation, Cancer Res, 68, 10205, 10.1158/0008-5472.CAN-08-2149 Larue, 2003, β-Catenin in the melanocyte lineage, Pigment Cell Res, 16, 312, 10.1034/j.1600-0749.2003.00050.x Martinez-Morales, 2007, New genes in the evolution of the neural crest differentiation program, Genome Biol, 8, R36, 10.1186/gb-2007-8-3-r36 Adameyko, 2009, Schwann cell precursors from nerve innervation are a cellular origin of melanocytes in skin, Cell, 139, 366, 10.1016/j.cell.2009.07.049 Ciuffreda, 2009, Growth-inhibitory and antiangiogenic activity of the MEK inhibitor PD0325901 in malignant melanoma with or without BRAF mutations, Neoplasia, 11, 720, 10.1593/neo.09398 Gray-Schopfer, 2005, The role of B-RAF in melanoma, Cancer Metastasis Rev, 24, 165, 10.1007/s10555-005-5865-1 Solit, 2007, 3′-Deoxy-3′-[18F]fluorothymidine positron emission tomography is a sensitive method for imaging the response of BRAF-dependent tumors to MEK inhibition, Cancer Res, 67, 11463, 10.1158/0008-5472.CAN-07-2976 Khaled, 2002, Glycogen synthase kinase 3β is activated by cAMP and plays an active role in the regulation of melanogenesis, J Biol Chem, 277, 33690, 10.1074/jbc.M202939200 Weinlich, 2006, Metallothionein—overexpression as a highly significant prognostic factor in melanoma: a prospective study on 1270 patients, Br J Cancer, 94, 835, 10.1038/sj.bjc.6603028 Endo, 2004, Immunohistochemical metallothionein expression in hepatocellular carcinoma: relation to tumor progression and chemoresistance to platinum agents, J Gastroenterol, 39, 1196, 10.1007/s00535-004-1471-1 Shimoda, 2003, Metallothionein is a potential negative regulator of apoptosis, Toxicol Sci, 73, 294, 10.1093/toxsci/kfg095 Poulikakos, 2010, RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF, Nature, 464, 427, 10.1038/nature08902 Hatzivassiliou, 2010, RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth, Nature, 464, 431, 10.1038/nature08833